Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB)

117 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q2 2025.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 27.9M shares of 45.1M outstanding shares and own 61.87% of the company stock.
Largest 10 shareholders include Paradigm Biocapital Advisors LP (4.24M shares), ACORN CAPITAL ADVISORS, LLC (3.42M shares), BlackRock, Inc. (2.75M shares), Caligan Partners LP (2.34M shares), Sofinnova Investments, Inc. (2.19M shares), VANGUARD GROUP INC (1.94M shares), Polar Capital Holdings Plc (1.79M shares), GEODE CAPITAL MANAGEMENT, LLC (848K shares), STATE STREET CORP (780K shares), and BOOTHBAY FUND MANAGEMENT, LLC (694K shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.